Clinical trial NCT03373227: Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen
Official title: Phase II, Single-Center, Open-Label Study Evaluating the Comparable Efficacy of Tacrolimus Extended Release Tablets (Envarsus®) to the Standard of Care (SOC) Twice Daily Tacrolimus (Prograf®) Dosing Regimen
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Heart Transplant Rejection
Graft Failure
Compliance, Patient
Keywords: Heart Transplant
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
First posted: 2017-12-14
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This phase II, single-center, open-label study will evaluate the comparable efficacy of tacrolimus extended release tablets (Envarsus®) to the standard of care (SOC) twice daily tacrolimus (Prograf®) dosing regimen post-cardiac transplantation.

Detailed description: This is a prospective, open-label, 2-arm, clinical trial to evaluate the efficacy of extended release tacrolimus (Envarsus) once-daily in comparison to Prograf capsules twice-daily after heart transplantation receiving the standard of care twice daily dosing with tacrolimus (Prograf).

Secondary objectives are to compare the compliance, safety and efficacy of once a day dosing (Envarsus) versus twice a day dosing (Prograf) and to evaluate the short term safety and tolerability of Envarsus.

Approximately 25 adult male or female recipients of a heart transplant will be prospectively enrolled to once-daily therapy with Envarsus tablets. Time of initiation will follow current standard of care. In addition, 25 age/gender-matched subjects who are receiving twice daily dosing with Prograf will be identified from the transplant center database and contacted to be consented, after which their results will be analyzed retrospectively.

The Termination Visit will occur on Day 182 (± 2 days) for subjects who complete the study treatment. Subjects who receive the first dose of study drug but withdraw from the study or terminate study treatment for any reason should complete all the procedures outlined for the Termination Visit.

The follow-up safety assessment may be conducted via telephone or at a study visit if needed for clinical follow-up on any safety issues). The follow-up safety assessment is to take place approximately 30 days (±5 days) after the last administration of study treatment, whether the subject completed study treatment or withdrew or terminated treatment early.

Eligibility criteria: Inclusion Criteria:

* Male or female, ≥ 18 years of age
* Able to comply with medication regimen
* Subjects must have the capacity to understand and sign the informed consent form
* Heart-only transplant recipients

Exclusion Criteria:

* Subject currently enrolled in another interventional research trial
* History of hypersensitivity/adverse reaction to tacrolimus
* Patient taking Rapamycin (sirolimus) or cyclosporine (Neoral/Gengraf)
* Simultaneous multiple organ transplant recipients
* Liver transplant recipients / candidates

Primary outcomes:
measure: Rejection and Graft Failure
timeFrame: 2 years
Secondary outcomes:
measure: Effect of Compliance on Rejection and Graft Failure
timeFrame: 2 years
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Baylor University Medical Center
state: Texas
Study officials:
affiliation: Baylor Health Care System
name: Shelley Hall, MD, FACC, FHFSA
role: PRINCIPAL_INVESTIGATOR
References: